Linagliptina Krka

Linagliptin, the active ingredient in Linagliptina Krka, is a DPP‑4 inhibitor presented as a tablet for oral use. It treats type 2 diabetes mellitus in adults by improving glycaemic control when combined with diet and exercise.

GNH USA supplies Linagliptina Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is used within the antidiabetic drug class to manage blood glucose levels in patients with type 2 diabetes mellitus.

- Type 2 diabetes mellitus (monotherapy): provides glycaemic control as a single oral agent. - Type 2 diabetes mellitus (combination therapy): used together with metformin, sulfonylureas or insulin to enhance glucose‑lowering effects. - Type 2 diabetes mellitus (renal impairment): can be administered without dose adjustment in patients with moderate to severe renal dysfunction.

Linagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nasopharyngitis: mild upper respiratory tract infection symptoms. - Headache: transient mild to moderate headache. - Gastrointestinal discomfort: includes nausea, abdominal pain or dyspepsia. - Dizziness: occasional light‑headed sensation. - Fatigue: feeling of tiredness without obvious cause.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with vomiting, requiring immediate medical attention. - Severe hypersensitivity reactions: including rash, angioedema or anaphylaxis. - Hepatic injury: elevated liver enzymes or jaundice. - Bullous pemphigoid: rare autoimmune skin blistering disorder. - Acute renal failure: abrupt decline in kidney function, though rare with linagliptin.

Before initiating linagliptin therapy, consider the following safety measures.

- Renal function: no dose adjustment required, but monitor renal parameters in severe impairment. - Hepatic impairment: use with caution and assess liver enzymes regularly. - Hypersensitivity: discontinue if signs of rash, swelling or anaphylaxis develop. - Pregnancy: safety not established; avoid unless benefits outweigh risks. - Elderly patients: monitor for hypoglycaemia when combined with insulin or sulfonylureas. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Linagliptin may interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong P‑gp inhibitors (e.g., itraconazole, clarithromycin): may increase linagliptin exposure. - Insulin or sulfonylureas: combined use can precipitate severe hypoglycaemia. - Rifampin: enzyme induction may reduce linagliptin plasma levels.

Moderate Interactions (Monitor Closely):\n- Diuretics: may affect glucose homeostasis, requiring glucose monitoring. - ACE inhibitors or ARBs: monitor blood pressure and renal function. - Warfarin: occasional reports of altered INR; check coagulation parameters regularly.